ROSNANO exits the portfolio Company NEARMEDIC PHARMA

ROSNANO exits the portfolio Company NEARMEDIC PHARMAROSNANO announced today that it has successfully exited pharmaceutical manufacturer NEARMEDIC PHARMA, a company it jointly established with Russian medical and pharmaceutical company NEARMEDIC PLUS. ROSNANO had held a 34.45 percent share in the authorized capital of the portfolio company. That interest was purchased for 2.3 billion rubles by project initiator NEARMEDIC PLUS. ROSNANO earned an internal rate of return of 41.1 percent on its investment.

The 1.3 billion rubles that ROSNANO extended in cofinancing was used mainly for construction of a manufacturing plant in Obninsk, in Kaluga Oblast. The complex, which is to be fully operational in 2014, covers 22,000 square meters. The general contractor, FormaPharm Engineering Group, has a large practice in design and construction of modern pharmaceutical plants in Europe and Russia, having built more than a dozen manufacturing facilities in recent years.

The new production complex in Obninsk is designed and equipped to handle the entire manufacturing cycle onsite in one production platform—from the synthesis of initial substances to the finished preparation—something unusual in the domestic industry. Construction for the new company makes it possible to significantly increase production of the antiviral drug Kagocel and to expand sales in markets in Russia and countries of the Commonwealth of Independent States. According to analyses from US-based IMS Health, a specialist in the pharmaceutical and health care industries, Kagocel was the number one antiviral drug purchased in the first three quarters of 2013, accounting for 19 percent of sales in this segment. Once the Obninsk plant goes online, NEARMEDIC will increase production of the drug and move all its manufacturing to the new facility.

“By placing its bets on development of original projects, like NEARMEDIC PHARMA, ROSNANO has opened the domestic pharmaceutical industry to intellectual advances by Russia’s academic scientists and to modern, GMP-compliant pharmaceutical production,” says the general director of NIARMEDIC PLUS, Vladimir Nesterenko.

Its sale of shares satisfies the two primary criteria for ROSNANO’s exit from an investment projects: a return at or above the planned level and a business capable of continuing to grow on its own.

“Drug development and production is one of the most science-intensive sectors of the economy. It is, as well, an area that requires considerable investment. Not every investor is going to be so brave as to place its resources in that kind of project. I am delighted that our financial support has helped promote Kagocel in markets in Russia and the CIS, expanding NEARMEDIC‘s market share tenfold in merely two years and beating our own forecasts of five years for a tenfold increase. That same investment allowed the manufacturer to build a state-of-the-art pharmaceutical production facility in Russia. This new plant meets all standards for the industry. The medicines produce there will be the equal of Western analogues, and in some cases, superior,” commented Olga Shpichko, ROSNANO managing director for investment activity, on the conclusion of the project.